| 摘要 |
Disclosed are a compound or crystalline form represented by formula I, pharmaceutically acceptable salts, and hydrate or solvate thereof. R1, R9, and R10 are respectively independently selected from halogen, H, deuterium, non-deuterated or partially deuterated or completely deuterated C1-C4 alkyl or C3-C6 cycloalkyl; R2-R8 are respectively independently selected from H, deuterium, not deuterated or partially deuterated or completely deuterated C1-C4 alkyl or C1-C4 cycloalkyl. The compound of the present invention has high peak drug concentration, high drug absorption, and long elimination half-life, and can improve drug efficacy in clinical usage and reduce frequency of drug administration. The compound or crystalline form and pharmaceutically acceptable salts thereof are selective uric acid reabsorption inhibitors, and can treat gout by promoting uric acid excretion from the body and reducing serum uric acid, providing a new choice for clinical medication. |
